Novo Nordisk reported DKK1.5B in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Bausch Health Companies USD 402M 5M Mar/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 121M 46M Jun/2026
Merck USD 525M 46M Jun/2026
Novartis USD 462M 119M Jun/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Sanofi EUR 287M 109M Jun/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023